Arcutis Canada, a subsidiary of Arcutis Biotherapeutics (ARQT), said Monday it has received approval from Health Canada for Zoryve to treat seborrheic dermatitis in patients aged 9 and older.
Trial data showed notable improvement in signs and symptoms, with the majority of patients experiencing reduced itching, scaling and redness, common burdens associated with seborrheic dermatitis, the company said.
Shares of the company were about 2% lower in recent trading.
Price: 8.56, Change: -0.16, Percent Change: -1.83
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。